Graduated in Biological Sciences from the Federal University of Rio de Janeiro (1978), Master's degree in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1982) and PhD in Biological Sciences (Biophysics) from the Federal University of Rio de Janeiro (1985) ). Conducted postdoctoral internships at the Max-Planck Institute in Tuebingen, Germany (1986/7), Vaccine Development Center at the University of Maryland, USA (1991), Department of Microbiology and Molecular Biology, Tufts University, USA (1992 ) and Department of Medical Microbiology at the University of Gothenburg, Sweden (1996). Visiting researcher at the Institute of Genetics, University of Bayreuth, Germany (2000-2005). Adjunct professor at the Biophysics and Radiobiology Department at the Federal University of Pernambuco (1983-1989) and at the Carlos Chagas Filho Biophysics Institute at the Federal University of Rio de Janeiro (1989-2000). He is currently a full professor (1999) and a full professor (2000) at the University of São Paulo and responsible for the Vaccine Development Laboratory in the Department of Microbiology at the Institute of Biomedical Sciences. Researcher 1A of the National Council for Scientific and Technological Development (until 2023). Coordinator of the Vaccine Research Support Center at USP. Vice-director of the USP Biomedical Sciences Institute (2013-2017). Director of the USP Biomedical Sciences Institute (2017-2021). Coordinator of the Scientific Platform Pasteur-USP (2018-2022). He received several awards related to scientific work and technological innovation. He has experience in the areas of Microbiology, Molecular Genetics and Microorganisms, immunology and vaccine development. He works on research related to the development of different vaccine strategies, among them research on vaccines aimed at controlling diarrhea caused by enteric bacteria (diarrhogenic Escherichia coli), dengue, dental caries and tumors induced by papillomavirus. He also conducts research related to the development of new vaccine adjuvants of a microbial nature. He develops projects in partnership with companies such as GSK, Instituto Butantan and Fundação Oswaldo Cruz. He has published about 200 scientific articles in specialized journals and has 9 patent applications filed with the INPI and / or PCT. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| Standing alone |
| Para caminar por sus propios medios |
| Avanza el coronavirus en Brasil |
| A villain with many faces |
| Un villano con muchas caras |
| A villain with many faces |
| Articles published in Pesquisa para Inovação FAPESP about the researcher: |
| FAPESP-funded startups are developing COVID-19 vaccines |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
The present grant application for a thematic research project has the main goal to offer financial support to different studies related to the Zika Vírus (ZIKV), presently under development at the Virology (LV) and Vaccine Research Laboratory (LDV) at the University of São Paulo (USP). The work is centered in four main themes: I) generation and application of ZIKV recombinant proteins aim…
Multi-user equipment approved in grant 2015/26228-3: SpeedVac (AU)
Currently, serological tests for antibodies detection that indicate previous infection by the dengue virus (DENV) are compromised by cross-reactivity with Zika virus antigens (ZIKV). In addition, there is no product commercially available products that differentiate DENV types (1 to 4) that patients were previously exposed to. This proposal aims to optimize the methodology for obtaining i…
The sudden appearance of a new viral pneumonia in late 2019 was the first of a series of events that led the world to a pandemic that in only 3 months has infected over one million people and reached over 200 countries and territories. The virus, named SARS-CoV-2, from the Coronaviridae family just like SARS and MERS, triggers a severe acute respiratory disease that leads to death in app…
(Only some records are available in English at this moment)
The outbreak of COVID-19, severe acute respiratory syndrome caused by coronavirus type 2 (SARS-CoV-2), began in China and spread around the world as a pandemic with more than 5 million deaths worldwide and more of 617 thousand deaths in Brazil. Even with the rapid development and distribution of vaccines to the population, the virus continues to spread around the world, thus maintaining t…
Cervical cancer stands out due to the high mortality rate worldwide. Despite the available treatments, cervical cancer is still considered a public health problem and new therapeutic approaches are needed. The objective of this project is to evaluate a treatment composed of immunotherapy based on bone marrow differentiated dendritic cells (BMDCs) activated in vitro by the recombinant prot…
In view of the current COVID-19 pandemic, the development of vaccination strategies against SARS-CoV-2 is a priority. Considering that risk groups are a priority, it is essential to develop vaccination strategies that have an adequate safety profile. In this context, subunits vaccines have been shown to be a promising alternative because they are safer, although they are often less immuno…
The current SARS-CoV-2 pandemics has infected 20 million people worldwide in seven months and demands immediate and accurate efforts to prevent its spread. The subunit vaccines proposed in this project will employ the SAPN technology (self-assembling protein nanoparticles) and are formulated with highly immunogenic fragments of structural proteins, particularly S and N (Spike and Nucleoca…
(Only some records are available in English at this moment)
The COVID-19 pandemic has been an unprecedented situation regarding its fast spread and the associated economical losses. Since late 2019 when it first emerged, SARS-CoV-2 has already caused millions of deaths worldwide and despite vaccination efforts continues to escalate. Even though several vaccines are already commercially available, they still face several limitations that open space…
Synthetic peptides have been described as potent and specific antiviral agents. Inhibitory peptides with effect on flaviviruses, including the arbovirus DENV and ZIKV, have also been investigated but so far no one is available for clinical use. On this line, our research group identified a peptide (Pep. 47), derived from DENV E protein domain III (EDIII) that have in vitro inhibitory effe…
Cervical cancer is the third leading cause of cancer death in women and is associated with persistent infection with Human Papilloma Virus (HPV) in more than 99% of the cases. Given the epidemiological relevance of tumors induced by HPV, development of effective therapeutic vaccines is a high priority. Therefore, we have developed a DNA-based therapeutic vaccine encoding the HPV-16 E7 pro…
(Only some records are available in English at this moment)
| 2 / 2 | Ongoing research grants |
| 29 / 19 | Completed research grants |
| 2 / 2 | Ongoing scholarships in Brazil |
| 71 / 31 | Completed scholarships in Brazil |
| 9 / 7 | Completed scholarships abroad |
| 113 / 61 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID